CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled
Drug / intervention
AZD7986 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02653872
NCT02653872Phase 1Completed

An Open-label, Non-randomized, Fixed Sequence Study Assessing the Pharmacokinetics of AZD7986 When Administered Alone and With Multiple Doses of Verapamil and Itraconazole or Diltiazem in Healthy Subjects

AstraZeneca·interventional·Posted Jan 12, 2016·Updated Feb 23, 2018

In Brief

A Phase 1 clinical trial evaluating AZD7986, Verapamil, and 2 other interventions for Healthy Subjects. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This is a phase 1, non-randomized, fixed sequence, 3-period, drug-drug interaction study to assess the pharmacokinetics (PK) of AZD7986 in healthy subjects when administered alone and in combination with multiple doses of verapamil and itraconazole or diltiazem

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 12, 2016
Enrollment StartJan 22, 2016
Primary CompletionApr 13, 2016
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 10.5 years ago

Interventions

AZD7986drug

Oral solution, single dose, dilution from concentrate

Verapamildrug

Extended release tablet for oral use

Itraconazoledrug

Oral solution

Diltiazemdrug

Extended release capsule